期刊文献+

炎症小体与中枢神经系统疾病关系的研究进展 被引量:2

Progress in Correlation of Inflammsome with Central Nervous System Diseases
下载PDF
导出
摘要 炎症小体(inflammasome)是由多种蛋白组成的复合物,能够调节促炎细胞因子前体半胱氨酸天冬氨酸蛋白酶(pro-caspases)的活化,进而在固有免疫防御系统中促进白细胞介素(IL)-1茁、IL-18和IL-33细胞因子前体的切割成熟,产生炎症应答。作为炎症反应的核心,炎症小体与阿尔茨海默病、脑脊髓炎、朊病毒病等中枢神经系统疾病的发生和发展密切相关。本文就炎症小体与中枢神经系统疾病关系的研究进展进行综述,希望为神经系统疾病的治疗提供新的方向和靶点。 Inflammasome is a multi-protein complex which can regulate the activation of the precursors of proinflammatory caspases, and promote the precursor forms of interleukin-1 β , IL-18 and IL-33 changing into their active forms in the innate immune defense system, hence resulting into a potent inflammatory response. As the core of the inflammatory response, inflammasome has close relationship with the occurrence and development of central nervous system(CNS) diseases, which included Alzheimer's disease, encephalomyelitis, Prion disease, etc. Here we review the progress in relationship between the inflammasome and CNS diseases, thus to provide the new theoretical direction and target of the treatment of CNS diseases in the future.
机构地区 三峡大学医学院
出处 《中药新药与临床药理》 CAS CSCD 北大核心 2014年第5期643-646,共4页 Traditional Chinese Drug Research and Clinical Pharmacology
基金 国家自然科学基金(81100957 81374001)
关键词 炎症小体 核苷酸结合寡聚域样受体 中枢神经系统疾病 Inflammasome Nueleotide-binding and oligomerization domain like receptor Central nervous systemdisease
  • 相关文献

参考文献2

二级参考文献108

  • 1Lin LF, Luo HM. Screening of treatment targets for Alzheim- er's disease from the molecular mechanisms of impairment by [3-amyloid aggregation and tau hyperphosphorylation. Neurosci Bull 2011,27: 53-60.
  • 2Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011, 3: 77sr71.
  • 3Winslow BT, Onysko MK, Stob CM, Hazlewood KA. Treat- ment of Alzheimer disease. Am Fam Physician 2011, 83: 1403-1412.
  • 4Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for AI- zheimer disease. Cold Spring Harb Perspect Med 2012, 2: a006395.
  • 5Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Ro- gers JT, et al. N-Methyl D-Aspartate (NMDA) receptor an- tagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res 2012, 9(6): 746-758.
  • 6Jo J, Whitcomb D J, Olsen KM, Kerrigan TL, Lo SC, Bru- Mercier G, et aL Abeta(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Aktl and GSK- 3beta. Nat Neurosci 2011, 14(5): 545-547.
  • 7Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated di- rectly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14: 837-842.
  • 8Shipton OA, Leitz JR, Dworzak J, Acton CE, Tunbridge EM,Denk F, et al. Tau protein is required for amyloid {beta}- induced impairment of hippocampal long-term potentiation. J Neurosci 2011, 31 : 1688-1692.
  • 9Peng S, Garzon D J, Marchese M, Klein W, Ginsberg SD, Francis BM, et al. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci 2009, 29: 9321-9329.
  • 10Van Muiswinkel FL, Veerhuis R, Eikelenboom P. Amyloid beta protein primes cultured rat microglial cells for an en- hanced phorbo112-myristate 13-acetate-induced respiratory burst activity. J Neurochem 1996, 66: 2468-2476.

共引文献7

同被引文献18

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部